Medical Aid & Weight-Loss Injections in SA

It is one of the most common questions we get, and the answer disappoints most people who ask it: in almost all cases, South African medical schemes do not pay for GLP-1 injections prescribed for weight loss.

That is not scheme obstinacy. It follows from how South African medical scheme law is structured, and understanding the structure tells you exactly where the exceptions are — because there are some.

How Medical Scheme Cover Actually Works Here

South African medical schemes operate under the Medical Schemes Act, overseen by the Council for Medical Schemes. At the centre of that framework sits a concept called Prescribed Minimum Benefits, or PMBs.

PMBs are a defined floor. Every registered scheme, on every plan, must cover the diagnosis, treatment and care costs of a specified set of conditions regardless of the plan you bought. According to the Council for Medical Schemes, that set comprises emergency medical conditions, roughly 271 defined diagnosis and treatment pairs, and 26 chronic conditions on what is called the Chronic Disease List.

The Chronic Disease List is the part that matters here. It includes conditions such as asthma, hypertension, epilepsy, HIV and — importantly — diabetes mellitus types 1 and 2.

It does not include obesity.

Why That Single Omission Decides Everything

Because obesity is not a PMB condition, schemes are under no legal obligation to fund treatment for it. Most do not.

This produces a situation that strikes many people as arbitrary but is entirely predictable once you see the logic:

• Semaglutide prescribed for type 2 diabetes is treatment for a PMB chronic condition. Schemes generally fund it, subject to their own clinical entry criteria, formularies and designated service providers.
• The identical molecule prescribed for weight management in someone without diabetes is treatment for a condition that is not a PMB. The scheme may decline, and usually does.

Discovery Health, the largest administrator in the country, covers GLP-1 agonists from the Chronic Illness Benefit for members registered for type 2 diabetes who meet its clinical criteria, and does not cover them for weight management in members without diabetes. Other large schemes have taken materially the same position. As of mid-2026 there was public discussion about widening access, and an acknowledgement that the health economics argument for doing so is strong, but no announced change to the eligibility criteria on the largest schemes.

A second point catches people out: Ozempic is not registered in South Africa for weight loss at all. It is registered for type 2 diabetes. Prescribing it for weight management is off-label, and schemes generally do not fund off-label use. Mounjaro's position changed in October 2025 when SAHPRA approved a chronic weight management indication for it, which removes the off-label problem for that product but does not make obesity a PMB condition or create a funding obligation.

Where There Is Genuine Room to Move

The situation is not uniformly hopeless. Several avenues are worth exploring properly rather than assuming the answer.

If you have type 2 diabetes or meet the criteria for it. This is the clearest route. Registration on the Chronic Illness Benefit with an appropriate diagnosis changes the funding question entirely. This is not an invitation to game a diagnosis — it is a reason to actually get tested if you have never had an HbA1c done. A meaningful number of people carrying significant weight are undiagnosed.

Savings and above-threshold benefits. Even where a scheme will not fund from risk, the medicine may be claimable from your medical savings account or, once you have crossed the annual threshold, from the above-threshold benefit on plans that have one. This is your own money, but it is money you may as well route through the correct channel.

Comorbidity-driven applications. Some schemes consider funding applications where obesity is driving a condition that is itself covered. It is not a guarantee, it usually requires motivation from your doctor with supporting clinical evidence, and it is decided case by case. It is worth a properly motivated application rather than a phone call.

Ex gratia applications. Most schemes have a process for funding outside the rules in exceptional circumstances. Approval rates are low and the process is slow, but it exists.

The Questions to Put to Your Scheme

Vague questions get vague answers. Ask precisely:

1. 1.Is this medicine on your formulary, and for which registered indication?
2. 2.What are the clinical entry criteria for funding, in writing?
3. 3.If I am registered for type 2 diabetes on the Chronic Illness Benefit, is this specific product funded, and at what co-payment?
4. 4.Is there a designated service provider I must use to avoid a co-payment?
5. 5.What is the process and the evidence requirement for a motivated funding application?
6. 6.Can I claim from savings or above-threshold if risk funding is declined?

Get the answers by email. Call-centre answers on this topic vary.

The Cost Reality, and Why It Drives Behaviour

With cover generally unavailable, the full cost falls on the individual. Registered tirzepatide in South Africa has been reported in the region of R2 800 to R5 500 a month depending on dose, and semaglutide pricing has moved with the arrival of generics and an authorised lower-cost option. Over the 12 to 18 months that trials suggest are needed for the full effect, that is a substantial commitment.

This gap is the direct reason a research-grade market exists in South Africa. We are not going to pretend otherwise, and we are not going to pretend the two things are equivalent. Research compounds are sold for research purposes, are not approved for human use, and carry no regulatory quality guarantee. A registered medicine dispensed on prescription carries oversight that a research compound does not.

If you are managing a diagnosed medical condition, the prescription route is the right route, and a funding fight with your scheme is worth having before you conclude it is unaffordable.

The Bottom Line

Medical schemes in South Africa are not required to fund weight-loss medication because obesity is not a Prescribed Minimum Benefit condition, and most schemes do not fund it. The exception that matters is type 2 diabetes, which is a PMB, and which changes the answer completely.

Before accepting a no, get your bloods done, ask your scheme the specific questions in writing, and check whether savings or above-threshold benefits can carry some of the cost. The rules are more navigable than the first phone call suggests.

Sources

The research, regulatory documents and clinical guidelines behind the claims in this article:

• Council for Medical Schemes. Prescribed Minimum Benefits, including the 26-condition Chronic Disease List. Council for Medical Schemes.
• South African Health Products Regulatory Authority. Frequently asked questions: semaglutide, including what is and is not registered in South Africa. SAHPRA.
• Aspen Pharmacare. Aspen secures SAHPRA approval for Mounjaro as a chronic weight management treatment (SENS announcement). Aspen Pharmacare, 2025.
• Wilding JPH, Batterham RL, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
• Jastreboff AM, Aronne LJ, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
• Rubino D, Abrahamsson N, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021.

Disclaimer: This article is general information about how medical scheme cover works in South Africa and is not financial, legal or medical advice. Scheme rules, formularies and registered indications change. Confirm your own position with your scheme and your prescribing practitioner. STRIATA peptides are research compounds and are not approved medicines.